Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk A/S has scrapped a partnership with Hims & Hers Health Inc after less than two months, saying the US company is ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

Last month, the two announced a partnership that would enable Wegovy to be directly purchased by patients via Hims’ ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must ...